Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Abstract

Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations. Methods In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged >or=18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease. The study was undertaken in 12 centres in Australia, Germany, Spain, Sweden, and the USA. The first cohort (n=33) was given continuous oral olaparib at the maximum tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily. The primary efficacy endpoint was objective response rate (ORR). This study is registered with ClinicalTrials.gov, number NCT00494442. Findings Patients had been given a median of three (range 1-16) previous chemotherapy regimens. ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily. In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, two [6%]), fatigue (grade 1 or 2, ten [30%]; grade 3 or 4, one [3%]), and anaemia (grade 1 or two, five [15%]; grade 3 or 4, one [3%]). The most freq…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)60893-8

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 58 references

Cited by

See all 2,279

Metadata

Authors
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., Lu, K., Schmutzler, R. K., Matulonis, U., Wickens, M., & Tutt, A.
Affiliations
  • Cedars-Sinai Medical Center (US)
  • AstraZeneca (United Kingdom) (GB)
  • Massachusetts General Hospital (US)
  • University of California, San Francisco (US)
  • The Royal Melbourne Hospital (AU)
  • City Of Hope National Medical Center (US)
  • Vall d'Hebron Hospital Universitari (ES)
  • Lund University (SE)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Cologne (DE)
  • Guy's Hospital (GB)
Corresponding author
Audeh, M William
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-07
Volume
376
Issue
9737
Pages
245-251
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2110017381
Cited by
2,279
References
58
Citations by year
2026: 16 · 2025: 42 · 2024: 66 · 2023: 77 · 2022: 96 · 2021: 108 · 2020: 122 · 2019: 141 · 2018: 163 · 2017: 189 · 2016: 218 · 2015: 188 · 2014: 205 · 2013: 191 · 2012: 202
FWCI
101.55
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • AstraZeneca
  • Susan G. Komen
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
olaparib, PARP inhibitors, BRCA1 mutation, BRCA2 mutation, recurrent ovarian cancer, synthetic lethality, oral chemotherapy, objective response rate, adverse events, dose comparison, germline mutation carriers, platinum-refractory disease, maintenance therapy, BRCA1/2 testing
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Adult, Aged, Antineoplastic Agents, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Phthalazines, Piperazines, Prospective Studies, Germ-Line Mutation, Genes, BRCA1, Maximum Tolerated Dose, Genes, BRCA2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60893-8
The paper
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., Lu, K., Schmutzler, R. K., Matulonis, U., Wickens, M., & Tutt, A. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet. https://doi.org/10.1016/s0140-6736(10)60893-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.